Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...

Vertiv Holdings ( NYSE: VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

Tesla stock inches up as the EV maker announces a $16.5 billion deal with Samsung Electronics. William Blair still remains ...

William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

As previously reported, William Blair downgraded NeoGenomics (NEO) to Market Perform from Outperform after the company reported Q2 results and cut ...

Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts ...

Larimar Therapeutics, Inc. ('Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing ...

Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...

CoStar’s second quarter saw solid execution, with revenue and non-GAAP earnings both surpassing Wall Street expectations, ...

SoFi Technologies shines in Q2 2025 with record revenue, robust member growth, blockchain & crypto innovation, and raised guidance.

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...